Early economic evaluation of MRI-guided laser interstitial thermal therapy (MRgLITT) and epilepsy surgery for mesial temporal lobe epilepsy

English version

Autoři: Elysa Widjaja ^aff001; Tina Papastavros ^aff004; Beate Sander ^aff001; Carter Snead ^aff003; Petros Pechlivanoglou ^aff001
Působiště autorů: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada ^aff001; Diagnostic Imaging, Hospital for Sick Children, Toronto, Canada ^aff002; Division of Neurology, Hospital for Sick Children, Toronto, Canada ^aff003; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada ^aff004; Toronto Health Economics Technology Assessment, University Health Network, Toronto, Canada ^aff005; Institute of Clinical Evaluative Sciences (ICES), Toronto, Canada ^aff006; Public Health Ontario, Toronto, Canada ^aff007; Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, Canada ^aff008
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0224571

Souhrn

Background

MRI-guided laser interstitial thermal therapy (MRgLITT) is a new minimally invasive treatment for temporal lobe epilepsy (TLE), with limited effectiveness data. It is unknown if the cost savings associated with shorter hospitalization could offset the high equipment cost of MRgLITT. We examined the cost-utility of MRgLITT versus surgery for TLE from healthcare payer perspective, and the value of additional research to inform policy decision on MRgLITT.

Methods

We developed a microsimulation model to evaluate quality adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER) of MRgLITT versus surgery in TLE, assuming life-time horizon and 1.5% discount rate. Model inputs were derived from the literature. We conducted threshold and sensitivity analyses to examine parameter uncertainties, and expected value of partial perfect information analyses to evaluate the expected monetary benefit of eliminating uncertainty on probabilities associated with MRgLITT.

Results

MRgLITT yielded 0.08 more QALYs and cost $7,821 higher than surgery, with ICER of $94,350/QALY. Influential parameters that could change model outcomes include probabilities of becoming seizure-free from disabling seizures state and returning to disabling seizures from seizure-free state 5 years after surgery and MRgLITT, cost of MRgLITT disposable equipment, and utilities of disabling seizures and seizure-free states of surgery and MRgLITT. The cost-effectiveness acceptability curve showed surgery was preferred in more than 50% of iterations. The expected monetary benefit of eliminating uncertainty for probabilities associated with MRgLITT was higher than for utilities associated with MRgLITT.

Conclusions

MRgLITT resulted in more QALYs gained and higher costs compared to surgery in the base-case. The model was sensitive to variations in the cost of MRgLITT disposable equipment. There is value in conducting more research to reduce uncertainty on the probabilities and utilities of MRgLITT, but priority should be given to research focusing on improving the precision of estimates on effectiveness of MRgLITT.

Klíčová slova:

Equipment – Magnetic resonance imaging – Surgical and invasive medical procedures – Cost-effectiveness analysis – Lasers – Hospitalizations – Minimally invasive surgery – Epilepsy

Zdroje

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–9. doi: 10.1056/NEJM200002033420503 10660394

2. Manjunath R, Paradis PE, Parise H, Lafeuille MH, Bowers B, Duh MS, et al. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology. 2012;79(18):1908–16. doi: 10.1212/WNL.0b013e318271f77e 23077014

3. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311–8. doi: 10.1056/NEJM200108023450501 11484687

4. Engel J Jr., McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. Jama. 2012;307(9):922–30. doi: 10.1001/jama.2012.220 22396514

5. Engel J Jr., Wiebe S, French J, Sperling M, Williamson P, Spencer D, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology. 2003;60(4):538–47. doi: 10.1212/01.wnl.0000055086.35806.2d 12601090

6. Lim ME, Bowen JM, Snead OC 3rd, Elliott I, Donner E, Weiss SK, et al. Access to surgery for paediatric patients with medically refractory epilepsy: a systems analysis. Epilepsy Res. 2013;107(3):286–96. doi: 10.1016/j.eplepsyres.2013.08.010 24192043

7. Ibrahim GM, Rutka JT, Snead OC, 3rd. Epilepsy surgery in childhood: no longer the treatment of last resort. CMAJ. 2014;186(13):973–4. doi: 10.1503/cmaj.140427 24914113

8. Waseem H, Vivas AC, Vale FL. MRI-guided laser interstitial thermal therapy for treatment of medically refractory non-lesional mesial temporal lobe epilepsy: Outcomes, complications, and current limitations: A review. J Clin Neurosci. 2017;38:1–7. doi: 10.1016/j.jocn.2016.12.002 28024732

9. Willie JT, Laxpati NG, Drane DL, Gowda A, Appin C, Hao C, et al. Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery. 2014;74(6):569–84; discussion 84–5. doi: 10.1227/NEU.0000000000000343 24618797

10. Kang JY, Wu C, Tracy J, Lorenzo M, Evans J, Nei M, et al. Laser interstitial thermal therapy for medically intractable mesial temporal lobe epilepsy. Epilepsia. 2016;57(2):325–34. doi: 10.1111/epi.13284 26697969

11. Burneo JG, Shariff SZ, Liu K, Leonard S, Saposnik G, Garg AX. Disparities in surgery among patients with intractable epilepsy in a universal health system. Neurology. 2016;86(1):72–8. doi: 10.1212/WNL.0000000000002249 26643546

12. CADTH Methods and Guidelines. Guidelines for the economic evaluation of health technologies: Canada. 4th edition. Ottawa: CADTH.2017

13. Germano IM, Poulin N, Olivier A. Reoperation for recurrent temporal lobe epilepsy. J Neurosurg. 1994;81(1):31–6. doi: 10.3171/jns.1994.81.1.0031 8207525

14. Goellner E, Bianchin MM, Burneo JG, Parrent AG, Steven DA. Timing of early and late seizure recurrence after temporal lobe epilepsy surgery. Epilepsia. 2013;54(11):1933–41. doi: 10.1111/epi.12389 24199826

15. Jung R, Aull-Watschinger S, Moser D, Czech T, Baumgartner C, Bonelli-Nauer S, et al. Is reoperation an option for patients with temporal lobe epilepsy after failure of surgery? Seizure. 2013;22(7):502–6. doi: 10.1016/j.seizure.2012.11.011 23273881

16. Salanova V, Markand O, Worth R. Temporal lobe epilepsy: analysis of failures and the role of reoperation. Acta Neurol Scand. 2005;111(2):126–33. doi: 10.1111/j.1600-0404.2005.00371.x 15644073

17. Gross RE, Stern MA, Willie JT, Fasano RE, Saindane AM, Soares BP, et al. Stereotactic Laser Amygdalohippocampotomy for Mesial Temporal Lobe Epilepsy. Ann Neurol. 2018;83(3):575–87. doi: 10.1002/ana.25180 29420840

18. Tao JX, Wu S, Lacy M, Rose S, Issa NP, Yang CW, et al. Stereotactic EEG-guided laser interstitial thermal therapy for mesial temporal lobe epilepsy. J Neurol Neurosurg Psychiatry. 2018;89(5):542–8. doi: 10.1136/jnnp-2017-316833 29183959

19. Georgiadis I, Kapsalaki EZ, Fountas KN. Temporal lobe resective surgery for medically intractable epilepsy: a review of complications and side effects. Epilepsy Res Treat. 2013;2013:752195. doi: 10.1155/2013/752195 24288602

20. Jain P, Tomlinson G, Snead C, Sander B, Widjaja E. Systematic review and network meta-analysis of resective surgery for mesial temporal lobe epilepsy. J Neurol Neurosurg Psychiatry. 2018;89(11):1138–44. doi: 10.1136/jnnp-2017-317783 29769251

21. Choi H, Sell RL, Lenert L, Muennig P, Goodman RR, Gilliam FG, et al. Epilepsy surgery for pharmacoresistant temporal lobe epilepsy: a decision analysis. JAMA. 2008;300(21):2497–505. doi: 10.1001/jama.2008.771 19050193

22. Wu C, Jermakowicz WJ, Chakravorti S, Cajigas I, Sharan AD, Jagid JR, et al. Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients. Epilepsia. 2019;60(6):1171–83. doi: 10.1111/epi.15565 31112302

23. Kang JY, Sperling MR. Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Treatment of Drug-Resistant Epilepsy. Neurotherapeutics. 2017;14(1):176–81. doi: 10.1007/s13311-016-0498-3 27905093

24. Krucoff MO, Chan AY, Harward SC, Rahimpour S, Rolston JD, Muh C, et al. Rates and predictors of success and failure in repeat epilepsy surgery: A meta-analysis and systematic review. Epilepsia. 2017;58(12):2133–42. doi: 10.1111/epi.13920 28994113

25. Hader WJ, Tellez-Zenteno J, Metcalfe A, Hernandez-Ronquillo L, Wiebe S, Kwon CS, et al. Complications of epilepsy surgery: a systematic review of focal surgical resections and invasive EEG monitoring. Epilepsia. 2013;54(5):840–7. doi: 10.1111/epi.12161 23551133

26. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr. 2004;9(2):98–101, 6–9. doi: 10.1017/s1092852900008464 14999166

27. Life Tables, Canada, Provinces and Territories 2010 to 2012. http://www.statcan.gc.ca/access_acces/alternative_alternatif.action?loc=/pub/84-537-x/2016006/2016006-eng.xlsx

28. Ontario Case Costing Initiative (OCCI). Health Data Branch Web Portal. Ministry of Health and Long Term Care. https://hsim.health.gov.on.ca/hdbportal/

29. Schedule of Benefits. Physician Services Under the Health Insurance Act. Ministry of Health and Long Term Care. http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20151221.pdf2015.

30. New Choice Health. https://www.newchoicehealth.com/places/california/ontario/

31. Langfitt JT, Holloway RG, McDermott MP, Messing S, Sarosky K, Berg AT, et al. Health care costs decline after successful epilepsy surgery. Neurology. 2007;68(16):1290–8. doi: 10.1212/01.wnl.0000259550.87773.3d 17438219

32. Ontario Drug Benefit Formulary. https://www.formulary.health.gov.on.ca/formulary/

33. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet. 2002;360(9334):711–5. doi: 10.1016/S0140-6736(02)09832-X 12241891

34. Ng R, Maxwell CJ, Yates EA, Nylen K, Antflick J, Jette N, et al. Brain Disorders in Ontario: Prevalence, Incidence and Costs from Health Administrative Data. ICES. Toronto, ONJuly 2015.

35. Census Profile, 2016 Census. Statistics Canada. http://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/Page.cfm?Lang=E&Geo1=PR&Code1=35&Geo2=&Code2=&Data=Count&SearchText=Ontario&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=35.

36. Ontario Population Projections Update, 2016–2041. Ontario Ministry of Finance. https://www.fin.gov.on.ca/en/economy/demographics/projections/.

37. Bowen JM, Snead OC, Chandra K, Blackhouse G, Goeree R. Epilepsy care in ontario: an economic analysis of increasing access to epilepsy surgery. Ont Health Technol Assess Ser. 2012;12(18):1–41. 23074428

38. Youngerman BE, Oh JY, Anbarasan D, Billakota S, Casadei CH, Corrigan EK, et al. Laser ablation is effective for temporal lobe epilepsy with and without mesial temporal sclerosis if hippocampal seizure onsets are localized by stereoelectroencephalography. Epilepsia. 2018;59(3):595–606. doi: 10.1111/epi.14004 29392715

39. Vakharia VN, Sparks R, Li K, O'Keeffe AG, Miserocchi A, McEvoy AW, et al. Automated trajectory planning for laser interstitial thermal therapy in mesial temporal lobe epilepsy. Epilepsia. 2018;59(4):814–24. doi: 10.1111/epi.14034 29528488

40. Drane DL, Loring DW, Voets NL, Price M, Ojemann JG, Willie JT, et al. Better object recognition and naming outcome with MRI-guided stereotactic laser amygdalohippocampotomy for temporal lobe epilepsy. Epilepsia. 2015;56(1):101–13. doi: 10.1111/epi.12860 25489630

41. Waseem H, Osborn KE, Schoenberg MR, Kelley V, Bozorg A, Cabello D, et al. Laser ablation therapy: An alternative treatment for medically resistant mesial temporal lobe epilepsy after age 50. Epilepsy Behav. 2015;51:152–7. doi: 10.1016/j.yebeh.2015.07.022 26280814

42. King JT Jr., Sperling MR, Justice AC, O'Connor MJ. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg. 1997;87(1):20–8. doi: 10.3171/jns.1997.87.1.0020 9202260

43. Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, et al. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016;57(10):1669–79. doi: 10.1111/epi.13492 27595433

44. Hinde S, Soares M, Burch J, Marson A, Woolacott N, Palmer S. The added clinical and economic value of diagnostic testing for epilepsy surgery. Epilepsy Res. 2014;108(4):775–81. doi: 10.1016/j.eplepsyres.2014.02.002 24630045

45. Micieli A, Bennell MC, Pham B, Krahn M, Singh SM, Wijeysundera HC. Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation. J Am Heart Assoc. 2014;3(5):e001031. doi: 10.1161/JAHA.114.001031 25227405

46. Oostenbrink JB, Al MJ, Oppe M, Rutten-van Molken MP. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health. 2008;11(7):1070–80. doi: 10.1111/j.1524-4733.2008.00389.x 19602213